Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Bio Manufacturers Poised To Follow Senate Victory With House Win
"A veteran California lawmaker with ties to the biotechnology industry said she thinks her proposal to protect brand-name biologic makers has enough support to carry in the House Energy and Commerce Committee," Dow Jones Newswires/Wall Street Journal reports. The proposal, by Rep. Anna Eshoo, D-Calif., would protect brand-name biologic products from competition for 12 years. A similar proposal cleared the Senate health committee earlier this week. Don't forget to buy zoloft online no prescription.

Two-Year Data Reinforce Effect Of ACTEMRA(R) (tocilizumab) In Inhibiting Progression Of Joint Damage And Improving Physical Function In Arthritis
Roche announced that two-year data from the LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) study demonstrated that ACTEMRA(R) (tocilizumab) continued to inhibit the progression of structural damage to joints in patients with rheumatoid arthritis (RA). The study also showed that patients receiving ACTEMRA experienced improved physical function, as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) scores(1). The LITHE study is the fifth international Phase III study in the extensive ACTEMRA clinical development program to successfully meet its primary endpoints in patients with moderately to severely active RA.

generic viagra online


News of the day
Daily Temperature Shifts May Alter Malaria Patterns
Daytime temperature fluctuations greatly alter the incubation period of malaria parasites in mosquitoes and alter transmission rates of the disease. Consideration of these fluctuations reveals a more accurate picture of climate change"s impact on malaria.
Diagnostics

South Africa Launches HIV/AIDS Vaccine Trial

"The first clinical trial of an HIV/AIDS vaccine designed and developed in South Africa was launched in Cape Town" Monday, the SAPA/The Times reports. The trial will seek to determine the immune response of HIV-negative people to two experimental vaccines -- SAAVI DNA-C2 and SAAVI MVA-C (7/20). Similar tests of the vaccine began in the U.S. earlier this year, the AP/Washington Post reports. The University of Cape Town developed the experimental vaccines with technical assistance and manufacturing of the vaccine provided by the NIH, according to Anthony Mbewu, president of South Africa"s Medical Research Council. "With 5.2 million already infected and with hundreds getting infected every day despite all the condom distribution and behavioral education programs, we know that a vaccine really is what we need," Mbewu said, adding, "When the next influenza pandemic hits the world, every country will be scrambling to develop a vaccine ... so it is important that countries like South Africa have the technology and capacity to develop vaccines and the industry to manufacture them" (Faul, 7/20). Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, called the partnership between South Africa and the U.S. "the most important AIDS research partnership in the world," but cautioned the years ahead would prove challenging as researchers test the safety and efficacy of the HIV vaccine, the AP/Google.com reports. "South Africa was the site of the biggest setback to AIDS vaccine research, when the most promising vaccine ever, produced by Merck & Co. and tested here in 2007, found that people who got the vaccine were more likely to contract HIV than those who did not," the news service writes, adding that "AIDS vaccine research is so filled with disappointments some activists are questioning the wisdom of continuing such expensive investments. They say the money might be better spent on prevention and education" (Faul, 7/20). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009